Filter Results
:
(1,010)
Show Results For
-
All HBS Web
(1,010)
- People (4)
- News (251)
- Research (595)
- Events (7)
- Multimedia (25)
- Faculty Publications (385)
Show Results For
-
All HBS Web
(1,010)
- People (4)
- News (251)
- Research (595)
- Events (7)
- Multimedia (25)
- Faculty Publications (385)
- September 1993
- Case
Manufacturing at ALZA: The Right Prescription? (A)
ALZA, a company specializing in drug delivery systems such as transdermal patches, considers manufacturing its own products. Until now, the company has conducted research and development on its patented system but has then licensed the technology to client-partner...
View Details
Keywords:
Business or Company Management;
Technological Innovation;
Innovation and Management;
Growth and Development Strategy;
Problems and Challenges;
Production;
Research and Development;
Organizational Change and Adaptation;
Pharmaceutical Industry;
Medical Devices and Supplies Industry
Leonard, Dorothy A. "Manufacturing at ALZA: The Right Prescription? (A)." Harvard Business School Case 694-019, September 1993.
- February 2001 (Revised July 2006)
- Case
Discovering the Future: R&D Strategy at Merck
By: Gary P. Pisano
Given explosive growth in technologies for drug discovery, how does Merck remain competitive in an industry that is fragmented and continues to consolidate?
View Details
Pisano, Gary P. "Discovering the Future: R&D Strategy at Merck." Harvard Business School Case 601-086, February 2001. (Revised July 2006.)
- September 1998 (Revised July 1999)
- Case
Discovery Health (B)
By: Samuel S. Chun and Shaun Matisonn
A South African health insurance company grapples with designing a financially viable coverage solution for a new prescription drug treatment for male impotence.
View Details
Keywords:
Motivation and Incentives;
Service Delivery;
Insurance;
Health Care and Treatment;
Insurance Industry;
South Africa
Chun, Samuel S., and Shaun Matisonn. "Discovery Health (B)." Harvard Business School Case 599-047, September 1998. (Revised July 1999.)
- February 2007 (Revised April 2010)
- Case
Wyeth Pharmaceuticals: Spurring Scientific Creativity with Metrics
By: Robert S. Huckman, Gary P. Pisano and Mark Rennella
Describes the reorganization of the drug discovery organization at Wyeth Pharmaceuticals and focuses on the decisions to: (1) centralize decision-making within drug discovery and (2) institute numerical metrics--jointly affecting all R&D scientists--for the progression...
View Details
Keywords:
Decision Making;
Measurement and Metrics;
Business Processes;
Organizational Structure;
Research and Development;
Science-Based Business;
Creativity;
Pharmaceutical Industry
Huckman, Robert S., Gary P. Pisano, and Mark Rennella. "Wyeth Pharmaceuticals: Spurring Scientific Creativity with Metrics." Harvard Business School Case 607-008, February 2007. (Revised April 2010.)
- August 2008 (Revised September 2008)
- Supplement
The Flaxil Label (C): Debrief and Endnotes
This case focuses on the 2001 negotiation between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The outcome of the negotiation would determine the new label for Mytex's blockbuster drug for arthritis, Flaxil. The negotiation is quite...
View Details
Keywords:
Safety;
Value Creation;
Negotiation;
Health Care and Treatment;
Sales;
Pharmaceutical Industry
Barron, Greg M. "The Flaxil Label (C): Debrief and Endnotes." Harvard Business School Supplement 909-003, August 2008. (Revised September 2008.)
- 09 Apr 2015
- News
Ariad Pharmaceuticals’ chief fights to hold on
- 17 May 2019
- News
Tackling high Rx prices
- 22 Feb 2016
- Research & Ideas
The ‘Mother of Fair Trade’ was an Unabashed Price Protectionist
of business. In 1927, R.L. McMaster opened Kut-Price drug outlets in Fresno and Modesto—as well as in Stockton. Gleason went on the offensive, coordinating Stockton’s Independent Merchants’ Association to open the town’s first...
View Details
- August 2008 (Revised September 2008)
- Case
The Flaxil Label (A)
This case focuses on the 2001 negotiation between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The outcome of the negotiation would determine the new label for Mytex's blockbuster drug for arthritis, Flaxil. The negotiation is quite...
View Details
Keywords:
Governing Rules, Regulations, and Reforms;
Health Disorders;
Product Launch;
Negotiation Process;
Business and Government Relations;
Safety;
Pharmaceutical Industry
Barron, Greg M. "The Flaxil Label (A)." Harvard Business School Case 909-001, August 2008. (Revised September 2008.)
- November 2020
- Case
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage...
View Details
Keywords:
Mergers and Acquisitions;
Value;
Valuation;
Judgments;
Decision Making;
Cash Flow;
Financial Instruments;
Cognition and Thinking;
Pharmaceutical Industry;
Biotechnology Industry;
United States
Esty, Benjamin C., and Daniel Fisher. "Valuing Celgene's CVR." Harvard Business School Case 221-031, November 2020.
- October 2014 (Revised April 2023)
- Case
Gilead: Hepatitis C Access Strategy (A)
By: V. Kasturi Rangan, Vikram Rangan and David E. Bloom
Gilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the...
View Details
Keywords:
Healthcare;
Pharmaceuticals;
Pricing;
Access To Care;
Emerging Markets;
Health Care and Treatment;
Price;
Strategy;
Ethics;
Health Industry;
Pharmaceutical Industry
Rangan, V. Kasturi, Vikram Rangan, and David E. Bloom. "Gilead: Hepatitis C Access Strategy (A)." Harvard Business School Case 515-025, October 2014. (Revised April 2023.)
- August 2020
- Article
Do Physician Incentives Increase Patient Medication Adherence?
By: Edward Kong, John Beshears, David Laibson, Brigitte Madrian, Kevin Volpp, George Loewenstein, Jonathan Kolstad and James J. Choi
We conducted a randomized experiment (911 primary care practices and 8,935 nonadherent patients) to test the effect of paying physicians for increasing patient medication adherence in three drug classes: diabetes medication, antihypertensives, and statins. We measured...
View Details
Keywords:
Health Economics;
Medication Adherence;
Physician Payment Incentives;
Primary Care;
Quality Improvement;
Health Care and Treatment;
Motivation and Incentives;
Behavior
Kong, Edward, John Beshears, David Laibson, Brigitte Madrian, Kevin Volpp, George Loewenstein, Jonathan Kolstad, and James J. Choi. "Do Physician Incentives Increase Patient Medication Adherence?" Health Services Research 55, no. 4 (August 2020): 503–511.
- November 2017
- Case
BeiGene
By: Willy Shih and Jimmy Zhang
BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window...
View Details
Keywords:
Biotechnology;
Pharmaceutical Company;
Pharmaceuticals;
China;
Regulatory Environment;
Business Strategy;
Business Startups;
Innovation Strategy;
Situation or Environment;
Pharmaceutical Industry;
China
Shih, Willy, and Jimmy Zhang. "BeiGene." Harvard Business School Case 618-033, November 2017.
- 19 Dec 2011
- News
A new investigation reveals a critical
- March 2024
- Article
Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act
By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti
The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that...
View Details
Keywords:
Policy;
Government Legislation;
Health Care and Treatment;
Negotiation;
Price;
Pharmaceutical Industry
Vogel, Matthew, Pragya Kakani, Amitabh Chandra, and Rena M. Conti. "Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act." Nature Biotechnology 42, no. 3 (March 2024): 406–412.
- April 2017
- Supplement
Imprimis (D)
By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case is a supplement to Imprimis (A, B, & C). It describes Imprimis’s 2015 decision to develop a $1 per pill compounded alternative to Daraprim, the branded drug that had recently undergone an extreme price hike, raising its price to $750 per pill. Imprimis also...
View Details
Keywords:
Decision Choices and Conditions;
Growth and Development Strategy;
Pharmaceutical Industry;
United States
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (D)." Harvard Business School Supplement 717-498, April 2017.
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the...
View Details
Keywords:
Decision Making;
Health Testing and Trials;
Innovation and Invention;
Markets;
Distribution;
Product Development;
Production;
Problems and Challenges;
Research;
Research and Development;
Complexity;
Biotechnology Industry;
Pharmaceutical Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (A)." Harvard Business School Case 603-043, April 2003. (Revised October 2004.)
- July 2008 (Revised September 2008)
- Case
Recent Developments in the Ranbaxy Case
By: Robert C. Pozen
This brief case describes settlements Indian drug maker Ranbaxy has made with Pfizer and AstraZeneca, as well as Daiichi Kangyo's purchase of a majority shareholding in Ranbaxy in 2008.
View Details
Keywords:
Mergers and Acquisitions;
Patents;
Lawsuits and Litigation;
Ownership Stake;
Pharmaceutical Industry;
India
Pozen, Robert C. "Recent Developments in the Ranbaxy Case." Harvard Business School Case 609-010, July 2008. (Revised September 2008.)
- Video
Dr. Yusuf Hamied
Dr. Yusuf Hamied, Chair of the pioneering Indian generic drugs company Cipla, discusses the timeline and strategies that allowed him to bring affordable HIV/AIDS treatments to market.
View Details
- September 2021 (Revised October 2022)
- Supplement
Hester Pharmaceuticals (B): Securing Supply
By: Dante Roscini and John Masko
Supplements the (A) case. In late 2020, demand for Hester Pharmaceutical’s (Hester’s) breakthrough oncology drug Akrozumab was outstripping the company’s most optimistic projections. In order to increase manufacturing capacity and meet the demand, Hester was...
View Details
Keywords:
COVID-19 Pandemic;
Cost vs Benefits;
Trade;
Supply Chain;
Global Strategy;
Buildings and Facilities;
Operations;
Health Care and Treatment;
Demand and Consumers;
Global Range;
Globalized Markets and Industries;
Pharmaceutical Industry;
Italy;
China;
United States;
Germany
Roscini, Dante, and John Masko. "Hester Pharmaceuticals (B): Securing Supply." Harvard Business School Supplement 722-009, September 2021. (Revised October 2022.)